The FDA received over 100 adverse event reports linked to compounded semaglutide products between 2023 and 2024. Most were preventable. Here is what distinguishes a safe compounded GLP-1 from a dangerous one — and how to verify which one you have.
By Dr. Teja V. Surapaneni, MD, MS • Board-Certified Internal Medicine • May 2026
The FDA received over 100 adverse event reports linked to compounded semaglutide products between 2023 and 2024. Most were preventable. Here is what distinguishes a safe compounded GLP-1 from a dangerous one — and how to verify which one you have.
Between 2022 and 2024, Ozempic and Wegovy were on the FDA drug shortage list. During a declared shortage, the FDA permits licensed compounding pharmacies to prepare copies of the shortage medication for individual patients. This created a legal — and for many patients, the only practical — pathway to semaglutide access when the branded products were unavailable or unaffordable.
The shortage has since been declared resolved for semaglutide by the FDA, which changes the legal landscape meaningfully. What has not changed is the underlying reality for most patients: branded Wegovy lists at $1,349/month, insurance coverage remains inconsistent, and compounded versions at $150–300/month remain the only financially viable option for the majority of people who need this medication.
Not all compounding pharmacies are equivalent. The regulatory framework creates two meaningfully different categories:
503B facilities are FDA-registered, subject to unannounced FDA inspections, and held to Current Good Manufacturing Practice (cGMP) standards — the same manufacturing framework applied to pharmaceutical companies. They can produce large batches without individual prescriptions and must meet sterility, potency, and identity testing requirements. A 503B facility is as close to pharmaceutical-grade manufacturing as compounding gets.
503A pharmacies compound per individual patient prescription under state pharmacy board oversight. Quality varies significantly — from excellent state-licensed facilities with rigorous internal standards to operations that would not survive an FDA inspection. 503A pharmacies are legal and serve an important role in individualized patient care, but the variability is real and the patient cannot always assess it from the outside.
With the semaglutide shortage resolved, 503B facilities can no longer compound semaglutide for general distribution. 503A pharmacies can still legally compound for individual patient prescriptions. This means the market has shifted almost entirely to 503A facilities, making pharmacy vetting more important than ever.
Before accepting any compounded semaglutide, confirm these five things:
The expansion of GLP-1 telehealth attracted operators who are not operating safely. Specific warning signs:
The 100+ adverse event reports the FDA received related to compounded semaglutide included dosing errors, hospitalizations for severe nausea and vomiting requiring IV hydration, and cases of hypoglycemia. The root causes in the reports included: incorrect concentration resulting in 10x overdose, no patient education on injection technique, no physician follow-up after adverse symptoms began, and products shipped without cold chain integrity.
None of these failures are inherent to compounded semaglutide. They are failures of the prescribing and dispensing process — all preventable with proper medical oversight.
In March 2025, the FDA declared the semaglutide shortage resolved. In practical terms this means:
The regulatory landscape continues to evolve. YourMD monitors FDA guidance and updates our pharmacy relationships accordingly.
Every compounded GLP-1 prescription we write goes to a 503A-licensed compounding pharmacy that meets all five verification criteria above. We require independent CoA documentation for each lot, confirm semaglutide base (not acetate), verify cold chain shipping protocols, and we do not prescribe to patients who have not completed a physician-reviewed intake with labs where indicated.
Our prescribing physicians are board-certified MDs — not nurse practitioners or PA protocols. Every prescription is reviewed by a physician, not generated algorithmically. This is not universal in the telehealth GLP-1 space and it matters for patient safety.
Compounded semaglutide can be safe. The safety is entirely dependent on the pharmacy and the prescribing process, not the molecule itself. The same active ingredient that is in a $1,349/month FDA-approved product can be compounded safely for a fraction of the cost when the pharmacy standards and physician oversight are in place. The difference between a safe program and an unsafe one is not the drug — it is the infrastructure around it.
This article is for informational purposes only and does not constitute medical advice. Always consult with a licensed physician before starting any medication.
No credit card required. Live MD consult included.